There is an unmet medical need of finding reliable methods for the diagnosis of calcific aortic valve disease (CAVD) at early stages. Approximately 2–4 % of people aged over 65 will develop CAVD, and 25 % of individuals in this age group with disease symptoms, have a 50 % increased risk of cardiovascular related events. Moreover, there is an associated risk of 80 % of progression over 5 years, to heart failure, aortic valve replacement or death. The early diagnosis of CAVD by detecting aortic valve calcification could allow us to improve patient´s clinical management.
CNIC researchers have identified four differentially expressed genes whose circulating expression levels can determine if a subject is suffering from aortic valve calcification, either in a clinical or subclinical stage. These genes can also be used for the differential diagnosis between CAVD and subclinical aortic-valve calcification. Diagnosis/biotech companies are sought for a license agreement.